In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy

Clostridioides difficile infection (CDI) is a leading cause of hospital-acquired diarrhea, which often stem from disruption of the gut microbiota by broad-spectrum antibiotics. The increasing prevalence of antibiotic-resistant C. difficile strains, combined with disappointing clinical trials results...

Descripción completa

Detalles Bibliográficos
Autores principales: Dureja, Chetna, Rutherford, Jacob T., Pavel, Fahad B. A., Norseeda, Krissada, Prah, Isaac, Sun, Dianqing, Hevener, Kirk E., Hurdle, Julian G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543012/
https://www.ncbi.nlm.nih.gov/pubmed/37790427
http://dx.doi.org/10.1101/2023.09.22.559005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543012/
https://www.ncbi.nlm.nih.gov/pubmed/37790427
http://dx.doi.org/10.1101/2023.09.22.559005

Ejemplares similares